Experience

Davis Polk advised Calyxt, Inc. in connection with its initial public offering of 8,050,000 shares of its common stock, including 1,050,000 shares of common stock sold pursuant to the full…

Davis Polk advised the joint bookrunners in connection with the initial public offering by Atacadão S.A. (“Grupo Carrefour Brasil”) and the selling shareholders of 297,143,842 common…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk advised an ad hoc group of lenders holding approximately $700 million of term loans in connection with an amendment of Synchronoss Technologies, Inc.’s $1.1 billion senior…

Davis Polk advised the joint global coordinators and representatives of the several underwriters in connection with the €756 million Rule 144A/Regulation S initial public offering of…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering of 11,000,000 shares of common stock of XPO Logistics, Inc. and advised the…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $7 billion aggregate principal amount of senior notes, consisting of $2 billion floating-rate…

Davis Polk advised the joint lead managers on an English law Regulation S only offering by ENN Energy Holdings Limited of its $600 million 3.25% bonds due 2022.  ENN Energy…

Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…